Lysosomal storage diseases: current therapies and future alternatives

AF Leal, AJ Espejo-Mojica, OF Sánchez… - Journal of Molecular …, 2020 - Springer
Lysosomal storage disorders (LSDs) are a group of monogenic diseases characterized by
progressive accumulation of undegraded substrates into the lysosome, due to mutations in …

[HTML][HTML] Models to study basic and applied aspects of lysosomal storage disorders

Á Gaudioso, TP Silva, MD Ledesma - Advanced Drug Delivery Reviews, 2022 - Elsevier
The lack of available treatments and fatal outcome in most lysosomal storage disorders
(LSDs) have spurred research on pathological mechanisms and novel therapies in recent …

Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic …

HY Song, CS Chien, AA Yarmishyn, SJ Chou, YP Yang… - Cells, 2019 - mdpi.com
Fabry disease (FD) is a rare inherited disorder characterized by a wide range of systemic
symptoms; it is particularly associated with cardiovascular and renal problems. Enzyme …

[HTML][HTML] Exploring the role of exosomes in the pathogenesis and treatment of cardiomyopathies: A comprehensive literature review

S FawzuAmeer, M Elsaka, S Kahtoon, RI Kerzabi… - Life Sciences, 2024 - Elsevier
Exosomes, a subset of small extracellular vesicles that play a crucial role in intercellular
communication, have garnered significant attention for their potential applications in the …

Human in vitro models for Fabry disease: new paths for unravelling disease mechanisms and therapies

C Borisch, T Thum, C Bär, J Hoepfner - Journal of Translational Medicine, 2024 - Springer
Fabry disease is a multi-organ disease, caused by mutations in the GLA gene and leading to
a progressive accumulation of glycosphingolipids due to enzymatic absence or malfunction …

Ion channels and pain in Fabry disease

C Weissmann, AA Albanese, NE Contreras… - Molecular …, 2021 - journals.sagepub.com
Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid
metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which …

Reversal of the inflammatory responses in Fabry patient IPSC-derived cardiovascular endothelial cells by CRISPR/Cas9-corrected mutation

HY Song, YP Yang, Y Chien, WY Lai, YY Lin… - International Journal of …, 2021 - mdpi.com
The late-onset type of Fabry disease (FD) with GLA IVS4+ 919G> A mutation has been
shown to lead to cardiovascular dysfunctions. In order to eliminate variations in other …

Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease

S Seemann, M Ernst, C Cimmaruta… - Biochemical …, 2020 - portlandpress.com
The lysosomal storage disorder Fabry disease is characterized by a deficiency of the
lysosomal enzyme α-Galactosidase A. The observation that missense variants in the …

The promises and pitfalls of CRISPR-mediated base editing in stem cells

PK Wong, NN Mohamad Zamberi… - The CRISPR …, 2023 - liebertpub.com
Stem cells such as induced pluripotent stem cells, embryonic stem cells, and hematopoietic
stem and progenitor cells are growing in importance in disease modeling and regenerative …

Advances in sphingolipidoses: CRISPR-Cas9 editing as an option for modelling and therapy

R Santos, O Amaral - International Journal of Molecular Sciences, 2019 - mdpi.com
Sphingolipidoses are inherited genetic diseases characterized by the accumulation of
glycosphingolipids. Sphingolipidoses (SP), which usually involve the loss of sphingolipid …